Modalis Therapeutics (4883.T) traded flat 0 % during a 24 hours period ending at 01:16 PM Central Europe on Tuesday 27th. One Modalis Therapeutics stock can currently be bought for about JPY 27 on popular exchanges. Current supply of Modalis Therapeutics stocks is 104.4 mn. Modalis Therapeutics has a current market capitalization of JPY 3 bn and approximately JPY 7.9 mn worth of Modalis Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Modalis Therapeutics has traded -12.5 % down. Simple moving average of last 200 days is at JPY 45.82. The highest price of past 52 weeks was recorded at JPY 83 on 04/30/2026. 52 weeks low was at JPY 27 on 10/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Muromachi Chemicals (4885.T) traded down -1.32 % and now trades at JPY 910. Muromachi Chemicals has a market capitalisation of JPY 3.6 bn. Current price/earnings ratio for Muromachi Chemicals is 64.32.

  • Correc (6578.T) traded down -0.41 % and now trades at JPY 480. Current market capitalisation for Correc is JPY 3.6 bn.

  • Takamisawa Cybernetics (6424.T) traded down -0.8 % and now trades at JPY 862. Takamisawa Cybernetics has a market capitalisation of JPY 3.6 bn. Current price/earnings ratio for Takamisawa Cybernetics is 11.97.

  • Transgenic (2342.T) traded up 5.31 % and now trades at JPY 211. Transgenic has a market capitalisation of JPY 3.6 bn. Transgenic has a current price to earnings ratio of 109.51. Cellectis announced at the European Society of Gene and Cell Therapy conference that its APOC3‑targeting base‑editing program, .HEAL‑101, achieved high editing efficiency in preclinical models and produced a marked reduction in triglyceride levels following a single administration. The company highlighted the potential of a one‑time treatment for severe hypertriglyceridemia and outlined plans to initiate a Phase 1 investigator‑initiated trial in China, with preliminary clinical data expected in late 2027. No other corporate developments or financial metrics were mentioned in the release.

  • Dwestern Therapeutics Insti (4576.T) traded down -1.56 % and now trades at JPY 62. Current market capitalisation for Dwestern Therapeutics Insti is JPY 3.6 bn.

About Modalis Therapeutics

The Modalis Therapeutics Corp is a biotechnology company based in Japan that operates on the Tokyo Stock Exchange.